poisar

Stock

Veracyte, Inc. VCYT

$38.52-4.02%

Overview

VCYT market data

Price History

VCYT price chart · 1M
O
41.19
H
41.19
L
38.27
C
38.52
Vol
162,330.00
Source
US equities market feed
Observed
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$41.19
Previous Close
$40.14
Day High
$41.19
Day Low
$38.27
52 Week High
$60.77
52 Week Low
$38.27
7 Day Return
-12.14%
30 Day Return
-8.43%
90 Day Return
-28.21%
1 Year Return
-7.60%
Daily Notional Volume
$6.3M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
28.70
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.82
Diluted earnings per share over the trailing twelve months.
Beta
2.03
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
20.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$29.46 – $60.91
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $3.3B · P/B 2.54 · P/S 5.85.

Company News

10 captured
Reasons to Retain Penumbra Stock in Your Portfolio for NowZacks Investment Research ·
Here's Why You Should Add BrightSpring Stock to Your Portfolio NowZacks Investment Research ·
Is This the Right Time to Retain Resmed Stock in Your Portfolio?Zacks Investment Research ·
8-K filing — VERACYTE, INC. (VCYT)SEC EDGAR ·
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock DownZacks Investment Research ·
Reasons to Retain Tandem Diabetes Stock in Your Portfolio NowZacks Investment Research ·
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA ClearanceZacks Investment Research ·
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?Zacks Investment Research ·

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock